{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:28:17Z","timestamp":1761676097583},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1177\/1933719113503408","type":"journal-article","created":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T07:44:59Z","timestamp":1380008699000},"page":"423-431","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Levonorgestrel Intrauterine System in Adjuvant Tamoxifen Treatment: Balance of Breast Risks and Endometrial Benefits\u2014Systematic Review of Literature"],"prefix":"10.1007","volume":"21","author":[{"given":"Salvatore","family":"Gizzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Di Gangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bertocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Noventa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Fagherazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tito Silvio","family":"Patrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"D\u2019Antona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Battista","family":"Nardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,30]]},"reference":[{"issue":"4","key":"21040423_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3322\/caac.20121","volume":"61","author":"R Siegel","year":"2011","unstructured":"Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212\u2013236.","journal-title":"CA Cancer J Clin."},{"issue":"17","key":"21040423_CR2","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1056\/NEJMoa050518","volume":"353","author":"DA Berry","year":"2005","unstructured":"Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784\u20131792.","journal-title":"N Engl J Med."},{"issue":"suppl 6","key":"21040423_CR3","doi-asserted-by":"publisher","first-page":"vi 12","DOI":"10.1093\/annonc\/mdr371","volume":"22","author":"S Aebi","year":"2011","unstructured":"Aebi S, Davidson T, Gruber G, Cardoso F; ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(suppl 6):vi 12\u2013vi 24.","journal-title":"Ann Oncol"},{"issue":"16","key":"21040423_CR4","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28(16):2784\u20132795.","journal-title":"J Clin Oncol"},{"issue":"3","key":"21040423_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509\u2013518.","journal-title":"J Clin Oncol"},{"key":"21040423_CR6","first-page":"CD007245","volume":"4","author":"J Chin","year":"2009","unstructured":"Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;(4):CD007245.","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"21040423_CR7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1097\/00006250-200606000-00057","volume":"107","author":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice","year":"2006","unstructured":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinio. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol. 2006;107(6): 1475\u20131478.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"21040423_CR8","first-page":"51","volume":"95","author":"L Mattson","year":"2012","unstructured":"Mattson L. Cost effectiveness in obstetrics and gynecology: the levonorgestrel intrauterine system. Minn Med. 2012;95(3):51\u201354.","journal-title":"Minn Med."},{"issue":"1","key":"21040423_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2133\/dmpk.DMPK-11-RV-084","volume":"27","author":"K Kiyotani","year":"2012","unstructured":"Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet. 2012;27(1):122\u2013131.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"18","key":"21040423_CR10","first-page":"4837","volume":"51","author":"EA Lien","year":"1991","unstructured":"Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991;51(18):4837\u20134844.","journal-title":"Cancer Res."},{"issue":"22","key":"21040423_CR11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","volume":"339","author":"CK Osborne","year":"1998","unstructured":"Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609\u20131618.","journal-title":"N Engl J Med."},{"issue":"6","key":"21040423_CR12","first-page":"1980","volume":"9","author":"EV Jensen","year":"2003","unstructured":"Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9(6):1980\u20131989.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"21040423_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tem.2011.01.005","volume":"22","author":"S Yang","year":"2011","unstructured":"Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011; 22(4):145\u2013152.","journal-title":"Trends Endocrinol Metab"},{"issue":"1-2","key":"21040423_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mce.2011.09.020","volume":"357","author":"HJ Lee","year":"2012","unstructured":"Lee HJ, Ormandy CJ. Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol. 2012;357(1\u20132):101\u2013107.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"21040423_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.maturitas.2006.07.003","volume":"56","author":"B Xu","year":"2007","unstructured":"Xu B, Kitawaki J, Koshiba H, et al. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. Maturitas. 2007;56(2):142\u2013152.","journal-title":"Maturitas"},{"issue":"1-2","key":"21040423_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mce.2011.10.030","volume":"357","author":"AE Obr","year":"2012","unstructured":"Obr AE, Edwards DP. The biology of progesterone receptor in thenormal mammary gland and in breast cancer. Mol Cell Endocrinol. 2012;357(1\u20132):4\u201317.","journal-title":"Mol Cell Endocrinol"},{"issue":"9243","key":"21040423_CR17","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(00)03204-9","volume":"356","author":"FJ Gardner","year":"2000","unstructured":"Gardner FJ, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000; 356(9243):1711\u20131717.","journal-title":"Lancet"},{"issue":"12","key":"21040423_CR18","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/j.1471-0528.2007.01545.x","volume":"114","author":"SS Chan","year":"2007","unstructured":"Chan SS, Tarn WH, Yeo W, et al. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG. 2007;114(12): 1510\u20131515.","journal-title":"BJOG"},{"issue":"3","key":"21040423_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/13697130802163168","volume":"11","author":"MD Kesim","year":"2008","unstructured":"Kesim MD, Aydin Y, Atis A, Mandiraci G. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric. 2008;11(3):252\u2013257.","journal-title":"Climacteric"},{"issue":"4","key":"21040423_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/01.AOG.0000178754.88912.b9","volume":"106","author":"T Backman","year":"2005","unstructured":"Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol. 2005;106(4):813\u2013817.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"21040423_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.contraception.2010.11.009","volume":"83","author":"J Dinger","year":"2011","unstructured":"Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83(3):211\u2013217.","journal-title":"Contraception"},{"issue":"1","key":"21040423_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.fertnstert.2007.05.033","volume":"90","author":"XB Trinh","year":"2008","unstructured":"Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008;90(1):17\u201322.","journal-title":"Fertil Steril"},{"issue":"2","key":"21040423_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ijc.24738","volume":"126","author":"HK Lyytinen","year":"2010","unstructured":"Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010; 126(2):483\u2013489.","journal-title":"Int J Cancer"},{"issue":"9793","key":"21040423_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793):771\u2013784.","journal-title":"Lancet"},{"issue":"10","key":"21040423_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.6004\/jnccn.2010.0083","volume":"8","author":"TB Bevers","year":"2010","unstructured":"Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010;8(10): 1112\u20131146.","journal-title":"J Natl Compr Canc Netw."},{"issue":"22","key":"21040423_CR26","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652\u20131662.","journal-title":"J Natl Cancer Inst."},{"issue":"18","key":"21040423_CR27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90(18):1371\u20131388.","journal-title":"J Natl Cancer Inst."},{"issue":"11","key":"21040423_CR28","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2002.20.11.2758","volume":"20","author":"DL Wickerham","year":"2002","unstructured":"Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20(11):2758\u20132760.","journal-title":"J Clin Oncol"},{"issue":"2","key":"21040423_CR29","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ygyno.2004.03.048","volume":"94","author":"I Cohen","year":"2004","unstructured":"Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94(2):256\u2013266.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"21040423_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1471-0528.2010.02552.x","volume":"117","author":"TJ Cade","year":"2010","unstructured":"Cade TJ, Quinn MA, Rome RM, Neesham D. Progestogen treatment options for early endometrial cancer. BJOG. 2010;117(7): 879\u2013884.","journal-title":"BJOG"},{"issue":"6","key":"21040423_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/IGC.0b013e3181aae1fb","volume":"19","author":"HS Hahn","year":"2009","unstructured":"Hahn HS, Yoon SG, Hong JS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19(6):1068\u20131073.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"21040423_CR32","first-page":"673","volume":"21","author":"MK Kim","year":"2011","unstructured":"Kim MK, Yoon BS, Park H, et al. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer. 2011;21(4):673\u2013677.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"21040423_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/GRF.0b013e318218607c","volume":"54","author":"MM Shah","year":"2011","unstructured":"Shah MM, Wright JD. Management of endometrial cancer in young women. Clin Obstet Gynecol. 2011;54(2):219\u2013225.","journal-title":"Clin Obstet Gynecol"},{"issue":"6","key":"21040423_CR34","doi-asserted-by":"publisher","first-page":"547.e1","DOI":"10.1016\/j.ajog.2010.07.037","volume":"203","author":"ID Gallos","year":"2010","unstructured":"Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.e1\u2013547.e10.","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"21040423_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1097\/OGX.0b013e318273570b","volume":"67","author":"AA Ewies","year":"2012","unstructured":"Ewies AA, Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet Gynecol Surv. 2012;67(11):726\u2013733.","journal-title":"Obstet Gynecol Surv."},{"issue":"2","key":"21040423_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.fertnstert.2005.01.129","volume":"84","author":"S Mirkin","year":"2005","unstructured":"Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005;84(2):485\u2013491.","journal-title":"Fertil Steril"},{"issue":"1","key":"21040423_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.maturitas.2006.03.010","volume":"55","author":"XB Trinh","year":"2006","unstructured":"Trinh XB, van Dam PA, Tjalma WA. Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: do they have any significance? Maturitas. 2006;55(1):94\u201395.","journal-title":"Maturitas"},{"issue":"5","key":"21040423_CR38","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/AOG.0b013e31828bf80c","volume":"121","author":"AW Wong","year":"2013","unstructured":"Wong AW, Chan SS, Yeo W, Yu MY, Tarn WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol. 2013;121(5):943\u2013950.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"21040423_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1530\/ERC-13-0020","volume":"20","author":"C Saccardi","year":"2013","unstructured":"Saccardi C, Gizzo S, Patrelli TS, et al. Endometrial surveillance in Tamoxifen users: role, timing and accuracy of hysteroscopic investigation. Observational longitudinal cohort study. Endocr Relat Cancer. 2013;20(4):455\u2013462.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"21040423_CR40","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/OGX.0b013e31828baef9","volume":"68","author":"S Gizzo","year":"2013","unstructured":"Gizzo S, Saccardi C, Patrelli TS, et al. Update on Raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013;68(6):467\u2013481.","journal-title":"Obstet Gynecol Surv."}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1177\/1933719113503408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1933719113503408","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1177\/1933719113503408\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1933719113503408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1177\/1933719113503408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T01:29:29Z","timestamp":1656811769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1177\/1933719113503408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["21040423"],"URL":"https:\/\/doi.org\/10.1177\/1933719113503408","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"30 December 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}